CEL-SCI (CVM) said Friday it closed a $5 million underwritten public offering of shares.
The company sold 2 million shares at $2.50 each in the offering.
CEL-SCI said it granted underwriters a 45-day option to buy up to an additional 190,000 shares to cover overallotments.
Net proceeds will be used for developing its investigational cancer treatment, Multikine, general corporate purposes, and working capital.